161 related articles for article (PubMed ID: 30602026)
41. Experience with pegvisomant in the treatment of acromegaly.
Drake WM
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
[TBL] [Abstract][Full Text] [Related]
42. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
Divisova J; Kuiatse I; Lazard Z; Weiss H; Vreeland F; Hadsell DL; Schiff R; Osborne CK; Lee AV
Breast Cancer Res Treat; 2006 Aug; 98(3):315-27. PubMed ID: 16541323
[TBL] [Abstract][Full Text] [Related]
43. Place of pegvisomant in acromegaly.
Ho KK
Lancet; 2001 Nov; 358(9295):1743-4. PubMed ID: 11734225
[No Abstract] [Full Text] [Related]
44. The role of pegvisomant in the treatment of acromegaly.
Roelfsema F; Biermasz NR; Pereira AM; Romijn JA
Expert Opin Biol Ther; 2008 May; 8(5):691-704. PubMed ID: 18407771
[TBL] [Abstract][Full Text] [Related]
45. Pegvisomant Pfizer/Sensus.
Goffin V; Touraine P
Curr Opin Investig Drugs; 2004 Apr; 5(4):463-8. PubMed ID: 15134290
[TBL] [Abstract][Full Text] [Related]
46. Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis.
Leonart LP; Ferreira VL; Tonin FS; Fernandez-Llimos F; Pontarolo R
Value Health; 2018 Jul; 21(7):874-880. PubMed ID: 30005760
[TBL] [Abstract][Full Text] [Related]
47. The ubiquitin-dependent endocytosis motif is required for efficient incorporation of growth hormone receptor in clathrin-coated pits, but not clathrin-coated lattices.
Sachse M; van Kerkhof P; Strous GJ; Klumperman J
J Cell Sci; 2001 Nov; 114(Pt 21):3943-52. PubMed ID: 11719561
[TBL] [Abstract][Full Text] [Related]
48. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly.
Higham CE; Rowles S; Russell-Jones D; Umpleby AM; Trainer PJ
J Clin Endocrinol Metab; 2009 Jul; 94(7):2459-63. PubMed ID: 19366854
[TBL] [Abstract][Full Text] [Related]
49. The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor.
Strous GJ; van Kerkhof P; Govers R; Ciechanover A; Schwartz AL
EMBO J; 1996 Aug; 15(15):3806-12. PubMed ID: 8670885
[TBL] [Abstract][Full Text] [Related]
50. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
Drake WM; Rowles SV; Roberts ME; Fode FK; Besser GM; Monson JP; Trainer PJ
Eur J Endocrinol; 2003 Dec; 149(6):521-7. PubMed ID: 14640992
[TBL] [Abstract][Full Text] [Related]
51. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
[TBL] [Abstract][Full Text] [Related]
52. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
[TBL] [Abstract][Full Text] [Related]
53. Clinical use of pegvisomant for the treatment of acromegaly.
Drake WM; Trainer PJ
Treat Endocrinol; 2003; 2(6):369-74. PubMed ID: 15981941
[TBL] [Abstract][Full Text] [Related]
54. Growth hormone receptor antagonists.
van der Lely AJ; Kopchick JJ
Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
[TBL] [Abstract][Full Text] [Related]
55. Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization.
Maamra M; Kopchick JJ; Strasburger CJ; Ross RJ
J Clin Endocrinol Metab; 2004 Sep; 89(9):4532-7. PubMed ID: 15356058
[TBL] [Abstract][Full Text] [Related]
56. The future of growth hormone antagonists.
van der Lely AJ
Curr Opin Pharmacol; 2002 Dec; 2(6):730-3. PubMed ID: 12482738
[TBL] [Abstract][Full Text] [Related]
57. Lessons from 6 years of GH receptor antagonist therapy for acromegaly.
Trainer PJ
J Endocrinol Invest; 2003; 26(10 Suppl):44-52. PubMed ID: 15497659
[TBL] [Abstract][Full Text] [Related]
58. Experience from the German pegvisomant observational study.
Strasburger CJ; Buchfelder M; Droste M; Mann K; Stalla GK; Saller B;
Horm Res; 2007; 68 Suppl 5():70-3. PubMed ID: 18174713
[TBL] [Abstract][Full Text] [Related]
59. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP
J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156
[TBL] [Abstract][Full Text] [Related]
60. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
